佰仁医疗(688198) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥66,005,581.98, representing a year-on-year increase of 26.34%[7] - Net profit attributable to shareholders was ¥13,606,919.59, reflecting a growth of 53.54% compared to the same period last year[7] - Basic earnings per share (EPS) was ¥0.14, up by 55.56% year-on-year[7] - Net profit for Q1 2022 reached CNY 13,570,614.66, compared to CNY 8,611,688.66 in Q1 2021, representing a significant increase of 57.5%[38] - The total comprehensive income for the period attributable to the parent company was CNY 13,780,828.74, compared to CNY 8,861,895.35 in the same period last year, representing a significant increase[41] Cash Flow - The net cash flow from operating activities reached ¥23,085,270.23, marking a significant increase of 73.21%[7] - Cash inflows from operating activities totaled CNY 71,507,150.55, compared to CNY 55,580,050.73 in the previous year, reflecting a growth of approximately 28.6%[45] - Net cash generated from operating activities was CNY 23,085,270.23, an increase from CNY 13,327,777.39 in the prior year, showing a year-over-year growth of about 73.5%[45] - The net increase in cash and cash equivalents for the period was CNY 32,896,749.65, compared to CNY 24,680,037.48 in the same period last year, indicating a growth of approximately 33.3%[47] - The ending balance of cash and cash equivalents was CNY 185,040,249.87, up from CNY 174,252,997.00 year-over-year[47] Research and Development - Total R&D investment amounted to ¥14,695,524.66, which is an increase of 43.25% from the previous year[9] - The proportion of R&D investment to operating revenue was 22.26%, an increase of 2.62 percentage points[9] - Research and development expenses for Q1 2022 were CNY 14,695,524.66, an increase of 43.0% compared to CNY 10,258,979.46 in Q1 2021[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,054,828,220.41, a 2.32% increase from the end of the previous year[9] - The company's total liabilities included accounts payable of ¥21.99 million, which increased from ¥15.30 million, indicating a growth of approximately 43.5%[30] - The company's total liabilities increased to CNY 47,665,564.92 from CNY 42,728,523.60, indicating a rise of 7.0%[35] - The total equity attributable to shareholders of the parent company rose to CNY 1,008,512,481.43 from CNY 989,510,316.64, reflecting a growth of 1.0%[35] Shareholder Information - The company reported a total of 2,000,853 shares held by China Industrial Bank Co., Ltd. - China Europe Value Smart Selection Mixed Securities Investment Fund, making it the largest shareholder[22] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest holding being 2,000,853 shares[22] - The company has a total of 561,070 shares held by Guoxin Securities - Bank of China - Guoxin Securities Dingxin No. 2 Science and Technology Innovation Board Strategic Placement Collective Asset Management Plan[22] Operating Costs and Revenue Segments - Total operating costs for Q1 2022 were CNY 52,611,993.70, up from CNY 46,798,690.45 in Q1 2021, reflecting a growth of 12.0%[35] - Revenue from the heart valve replacement and repair segment grew by 28.29%, with artificial biological heart valve sales increasing by 44.91%[10]